col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


244 Results       Page 1

 [1] 
Elsevier: The Lancet Rheumatology
  original article Date Title Authors   All Authors
1 [GO] 2024―May―08 Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial Carl S Goodyear, Amit Patel, Eleanor Barnes, Michelle Willicombe, Stefan Siebert, Thushan I de Silva, et al. (+115)
2 [GO] 2024―May―08 Additional SARS-CoV-2 vaccine doses: a little is better than none Alfred H J Kim
3 [GO] 2024―Jan―22 Pandemic to endemic: optimising COVID-19 immunity The Lancet Rheumatology
4 [GO] 2023―Dec―12 Improving COVID-19 vaccine response in individuals receiving methotrexate Katie Bechman, James Galloway
5 [GO] 2023―Dec―12 Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial Abhishek Abhishek, Nicholas Peckham, Corinna Pade, Joseph M Gibbons, Lucy Cureton, Anne Francis, et al. (+62)
6 [GO] 2023―Nov―15 Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial Jennifer S Hanberg, Xiaoqing Fu, Xiaosong Wang, Naomi J Patel, Yumeko Kawano, Abigail Schiff, et al. (+12)
7 [GO] 2023―Aug―31 Technology, COVID-19, and approaching the insoluble problems of gout care Kanon Jatuworapruk, Rebecca Grainger
8 [GO] 2023―Aug―31 Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY Mark D Russell, Jon Massey, Edward Roddy, Brian MacKenna, Seb Bacon, Ben Goldacre, et al. (+15)
9 [GO] 2023―Jul―25 The impact of COVID-19 on rheumatology health-care workers and their scientific output: heavy lies the crown on women in rheumatology Margaret R Andrews, Chiara Kirchler, Erika Mosor, Kylie Thaler, Tanja Stamm, Christina Duftner, Ruth Fritsch-Stork
10 [GO] 2023―Jul―25 Predicting COVID-19 vaccination response in populations who are immunosuppressed Katie Bechman, Mark D Russell, James B Galloway
11 [GO] 2023―Jul―25 Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY Fiona A Pearce, Sean H Lim, Mary Bythell, Peter Lanyon, Rachel Hogg, Adam Taylor, et al. (+10)
12 [GO] 2023―Jun―02 Rheumatology congresses post COVID-19: we cannot regress Lena Bugge Nordberg, Jens Vikse, Marte Schrumpf Heiberg, Even Lillejordet, Marthe Thoresen Mæhlen, Eirik Klami Kristianslund, et al. (+2)
13 [GO] 2023―May―31 Long COVID in inflammatory rheumatic diseases-what's in a name? Leonard H Calabrese
14 [GO] 2023―Apr―24 Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study Parikshit Sen, Naveen R, Arvind Nune, Jessica Day, Mrudula Joshi, Vikas Agarwal, et al. (+2)
15 [GO] 2023―Jan―23 Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study Grace Qian, Xiaosong Wang, Naomi J Patel, Yumeko Kawano, Xiaoqing Fu, Claire E Cook, et al. (+10)
16 [GO] 2023―Jan―23 Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease Katie Bechman, James Galloway
17 [GO] 2023―Jan―10 Navigating use of rituximab during the COVID-19 pandemic Mehreen Elahee, Sebastian E Sattui
18 [GO] 2023―Jan―10 Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study Md Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, Claire Vandevelde, Shouvik Dass, Sinisa Savic, et al. (+2)
19 [GO] 2022―Nov―25 Withholding methotrexate after COVID-19 vaccination: different strategies, same results? Ana C De Medeiros-Ribeiro, Carlo S Renner Araujo, Eloisa Bonfa
20 [GO] 2022―Nov―25 Withholding methotrexate after COVID-19 vaccination: different strategies, same results? - Author's reply Pankti Mehta, Sakir Ahmed, Padmanabha Shenoy, Teny Grace Skaria, Aby Paul
21 [GO] 2022―Nov―16 Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study Kristin H Bjørlykke, Hilde S Ørbo, Anne T Tveter, Ingrid Jyssum, Joseph Sexton, Trung T Tran, et al. (+15)
22 [GO] 2022―Nov―04 The impact of COVID-19 on care of early inflammatory arthritis in the UK Elizabeth MacPhie, Laura C Coates
23 [GO] 2022―Nov―04 Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY Mark D Russell, James B Galloway, Colm D Andrews, Brian MacKenna, Ben Goldacre, Amir Mehrkar, et al. (+12)
24 [GO] 2022―Oct―03 Long COVID: defining the role of rheumatology in care and research Leonard H Calabrese, Cassandra M Calabrese
25 [GO] 2022―Sep―13 Suspending methotrexate for 2 weeks after COVID-19 vaccination Laura C Coates, Abhishek Abhishek
26 [GO] 2022―Sep―13 Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials Teny Grace Skaria, Anu Sreeprakash, Rashwith Umesh, Sneha Joseph, Manju Mohan, Sakir Ahmed, et al. (+14)
27 [GO] 2022―Sep―13 Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study Gabriel Figueroa-Parra, Emily L Gilbert, Maria O Valenzuela-Almada, Sebastian Vallejo, Matthew R Neville, Naomi J Patel, et al. (+13)
28 [GO] 2022―Sep―13 Increased risk of severe COVID-19 outcomes in patients with rheumatoid arthritis and interstitial lung disease Clive Kelly
29 [GO] 2022―Aug―26 Potential for false decline of anti-SARS-CoV-2 spike antibody titers after COVID-19 vaccination Meryl Waldman, David B Sacks, Lilian Howard, Justine Cole
30 [GO] 2022―Aug―23 SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period Laura Boekel, Yaëlle R Besten, Femke Hooijberg, Rosa Wartena, Maurice Steenhuis, Erik Vogelzang, et al. (+17)
31 [GO] 2022―Aug―16 Preventive medicine in rheumatology: COVID-19 and its lessons for better health outcomes David F L Liew, Philip C Robinson
32 [GO] 2022―Aug―16 COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study Malcolm Risk, Salim S Hayek, Elena Schiopu, Liyang Yuan, Chen Shen, Xu Shi, et al. (+2)
33 [GO] 2022―Aug―09 Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study David Simon, Koray Tascilar, Filippo Fagni, Arnd Kleyer, Gerhard Krönke, Christine Meder, et al. (+27)
34 [GO] 2022―Aug―09 SARS-CoV-2 vaccine-induced antibody levels: what lies beneath Ria Lassaunière, Caroline T Tiemessen
35 [GO] 2022―Jul―25 Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study Zara Izadi, Milena A Gianfrancesco, Gabriela Schmajuk, Lindsay Jacobsohn, Patricia Katz, Stephanie Rush, et al. (+296)
36 [GO] 2022―Jul―21 Systemic sclerosis in the time of COVID-19 Anna-Maria Hoffmann-Vold, Oliver Distler, Cosimo Bruni, Christopher P Denton, Jeska de Vries-Bouwstra, Marco Matucci Cerinic, et al. (+2)
37 [GO] 2022―Jul―12 Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City Amit Saxena, Alexis J Engel, Brittany Banbury, Ghadeer Hasan, Nicola Fraser, Devyn Zaminski, et al. (+11)
38 [GO] 2022―Jun―09 Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform Brian MacKenna, Nicholas A Kennedy, Amir Mehrkar, Anna Rowan, James Galloway, Julian Matthewman, et al. (+42)
39 [GO] 2022―Jun―09 Racial and ethnic differences in COVID-19 outcomes: a call to action Philip C Robinson, Jinoos Yazdany
40 [GO] 2022―Apr―29 Immunosuppression and SARS-CoV-2 breakthrough infections Alfred H J Kim, Jeffrey A Sparks
41 [GO] 2022―Apr―29 Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies Laura Boekel, Eileen W Stalman, Luuk Wieske, Femke Hooijberg, Koos P J van Dam, Yaëlle R Besten, et al. (+81)
42 [GO] 2022―Apr―27 Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis Rachel Wallwork, Caoilfhionn M Connolly, Matthew Shneyderman, Zsuzsanna McMahan, Christopher A Mecoli, Fredrick Wigley, et al. (+3)
43 [GO] 2022―Apr―14 Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases Jeffrey A Sparks, Namrata Singh, Zachary S Wallace
44 [GO] 2022―Apr―14 Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis Jessica Widdifield, Jeffrey C Kwong, Simon Chen, Lihi Eder, Eric I Benchimol, Gilaad G Kaplan, et al. (+5)
45 [GO] 2022―Apr―01 Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease Rebecca H Haberman, Seungha Um, Jordan E Axelrad, Rebecca B Blank, Zakwan Uddin, Sydney Catron, et al. (+17)
46 [GO] 2022―Mar―29 No perfect therapy for the imperfect COVID-19 cytokine storm Randy Q Cron
47 [GO] 2022―Mar―29 Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial MeiLan K Han, Martti Antila, Joachim H Ficker, Ivan Gordeev, Alfredo Guerreros, Amparo Lopez Bernus, et al. (+14)
48 [GO] 2022―Mar―29 IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2 Hamid Bassiri, Scott W Canna
49 [GO] 2022―Mar―29 Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases Caoilfhionn M Connolly, Teresa Po-Yu Chiang, Mayan Teles, Sarah Frey, Jennifer L Alejo, Allan Massie, et al. (+6)
50 [GO] 2022―Mar―25 Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies - Authors' reply Matthias B Moor, Franziska Suter-Riniker, Cedric Hirzel, Britta Maurer, Daniel Sidler
51 [GO] 2022―Mar―25 Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies Pavan Bhargava
52 [GO] 2022―Mar―17 Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, Eileen W Stalman, Laura Y L Kummer, Zoé L E van Kempen, et al. (+69)
53 [GO] 2022―Mar―17 Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal Caoilfhionn M Connolly, Julie J Paik
54 [GO] 2022―Mar―15 Sulfasalazine: a risk factor for severe COVID-19? Maximilian F Konig, Katarzyna M Grzes, Philip C Robinson, Edward J Pearce
55 [GO] 2022―Feb―24 Severe COVID-19 as a virus-independent immunothrombotic process Robin Cherian, Moon Ley Tung, Bharatendu Chandra
56 [GO] 2022―Feb―24 Severe COVID-19 as a virus-independent immunothrombotic process - Authors' reply Dennis McGonagle, Abdulla Watad, Charles Bridgewood
57 [GO] 2022―Feb―09 COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey Michael Putman, Kevin Kennedy, Emily Sirotich, Jean W Liew, Sebastian E Sattui, Tarin T Moni, et al. (+48)
58 [GO] 2022―Feb―09 COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases Laura Boekel, Femke Hooijberg, Yaëlle R Besten, Erik H Vogelzang, Maurice Steenhuis, Maureen Leeuw, et al. (+14)
59 [GO] 2022―Feb―07 Health-care workers recovered from natural SARS-CoV-2 infection should be exempt from mandatory vaccination edicts Dennis G McGonagle
60 [GO] 2022―Feb―03 COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1 Benazir Saleem, Rebecca L Ross, Laurence Duquenne, Pam Hughes, Paul Emery
61 [GO] 2022―Jan―28 Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study Ruth K Topless, Angelo Gaffo, Lisa K Stamp, Philip C Robinson, Nicola Dalbeth, Tony R Merriman
62 [GO] 2022―Jan―28 Women with gout and COVID-19-an unfortunate combination? Christoffer B Nissen, Oliver Hendricks, Karen Schreiber
63 [GO] 2022―Jan―28 Novel COVID-19 therapies: the road ahead for rheumatology The Lancet Rheumatology
64 [GO] 2022―Jan―18 Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study Jessica K Gordon, Kimberly Showalter, Yin Wu, Linda Kwakkenbos, Marie-Eve Carrier, Richard S Henry, et al. (+9)
65 [GO] 2022―Jan―18 Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease Sarah Frey, Teresa Po-Yu Chiang, Caoilfhionn M Connolly, Mayan Teles, Jennifer L Alejo, Brian J Boyarsky, et al. (+5)
66 [GO] 2021―Dec―24 Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients L Boekel, G J Wolbink
67 [GO] 2021―Dec―24 Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study Ingrid Jyssum, Hassen Kared, Trung T Tran, Anne T Tveter, Sella A Provan, Joseph Sexton, et al. (+16)
68 [GO] 2021―Dec―21 Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab Jitka Smetanova, Zuzana Strizova, Anna Sediva, Tomas Milota, Rudolf Horvath
69 [GO] 2021―Dec―13 Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries Lina El Kibbi, Mona Metawee, Ihsane Hmamouchi, Nizar Abdulateef, Hussein Halabi, Mervat Eissa, et al. (+9)
70 [GO] 2021―Dec―08 Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination Medha Barbhaiya, Jonah M Levine, Vivian P Bykerk, Lisa A Mandl
71 [GO] 2021―Dec―03 Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease Xing-Su Gao, Feng-Cai Zhu
72 [GO] 2021―Dec―03 Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study Nadia E Aikawa, Leonard V K Kupa, Sandra G Pasoto, Ana C Medeiros-Ribeiro, Emily F N Yuki, Carla G S Saad, et al. (+17)
73 [GO] 2021―Dec―03 Mental health before and during the pandemic in people with systemic sclerosis Richard S Henry, Linda Kwakkenbos, Marie-Eve Carrier, Zelalem Negeri, Angelica Bourgeault, Scott Patten, et al. (+5)
74 [GO] 2021―Dec―02 Therapeutic implications of ongoing alveolar viral replication in COVID-19 Dennis McGonagle, Mary F Kearney, Anthony O'Regan, James S O'Donnell, Luca Quartuccio, Abdulla Watad, Charles Bridgewood
75 [GO] 2021―Nov―23 Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases Padmanabha Shenoy, Sakir Ahmed, Aby Paul, Somy Cherian, Rashwith Umesh, Veena Shenoy, et al. (+4)
76 [GO] 2021―Nov―17 Who, what, and when-effective therapy for severe COVID-19 Daniel A Kelmenson, Randy Q Cron
77 [GO] 2021―Nov―17 Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial Xavier Mariette, Olivier Hermine, Pierre-Louis Tharaux, Matthieu Resche-Rigon, Raphael Porcher, Philippe Ravaud, et al. (+597)
78 [GO] 2021―Nov―15 What does endemic COVID-19 mean for the future of rituximab? David F L Liew, Philip C Robinson
79 [GO] 2021―Nov―15 Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative Kathleen M Andersen, Benjamin A Bates, Emaan S Rashidi, Amy L Olex, Roslyn B Mannon, Rena C Patel, et al. (+10)
80 [GO] 2021―Nov―09 Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study Satveer K Mahil, Katie Bechman, Antony Raharja, Clara Domingo-Vila, David Baudry, Matthew A Brown, et al. (+15)
81 [GO] 2021―Nov―09 Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis Laura Boekel
82 [GO] 2021―Nov―08 Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab Renaud Felten, Floriane Gallais, Cédric Schleiss, Emmanuel Chatelus, Rose-Marie Javier, Luc Pijnenburg, et al. (+5)
83 [GO] 2021―Nov―06 Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study Sebastian E Sattui, Richard Conway, Michael S Putman, Andrea M Seet, Milena A Gianfrancesco, Kaley Beins, et al. (+305)
84 [GO] 2021―Nov―06 COVID-19 in systemic vasculitis and polymyalgia rheumatica: who is at risk of poor outcomes? Sara Monti
85 [GO] 2021―Oct―29 IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19 Emanuel Della-Torre, Elena Criscuolo, Marco Lanzillotta, Massimo Locatelli, Nicola Clementi, Nicasio Mancini, Lorenzo Dagna
86 [GO] 2021―Oct―28 COVID-19: is the rush to boost backed by science? The Lancet Rheumatology
87 [GO] 2021―Oct―22 Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies Savino Sciascia, Piera Costanzo, Massimo Radin, Karen Schreiber, Massimo Pini, Antonella Vaccarino, et al. (+3)
88 [GO] 2021―Oct―12 Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry Raphaèle Seror, Marine Camus, Jean-Hugues Salmon, Christian Roux, Emmanuelle Dernis, André Basch, et al. (+12)
89 [GO] 2021―Sep―30 Cutaneous vasculitis following COVID-19 vaccination Giulio Cavalli, Serena Colafrancesco, Giacomo De Luca, Nathalie Rizzo, Roberta Priori, Fabrizio Conti, Lorenzo Dagna
90 [GO] 2021―Sep―29 Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination Sarah Frey, Caoilfhionn M Connolly, Teresa Po-Yu Chiang, Mayan Teles, Jennifer L Alejo, Brian J Boyarsky, et al. (+4)
91 [GO] 2021―Sep―27 Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine Bryant Furlow
92 [GO] 2021―Sep―14 Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19 Meriam Islam, Munazzah Chou, Tasanee Braithwaite, Ata Siddiqui
93 [GO] 2021―Sep―07 Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study Matthias B Moor, Franziska Suter-Riniker, Michael P Horn, Daniel Aeberli, Jennifer Amsler, Burkhard Möller, et al. (+14)
94 [GO] 2021―Sep―07 B cells: more than just for antibodies in SARS-CoV-2 vaccine responses Michael A Paley, Alfred H J Kim
95 [GO] 2021―Aug―28 COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses Filippo Fagni, David Simon, Koray Tascilar, Verena Schoenau, Michael Sticherling, Markus F Neurath, Georg Schett
96 [GO] 2021―Aug―26 COVID-19 vaccine data provide reassurance The Lancet Rheumatology
97 [GO] 2021―Aug―16 Haemophagocytic lymphohistiocytosis secondary to COVID-19: a case series Luke Flower, Nick Laundy, Maryam Khosravi, Jim Buckley, Aislinn Gale, Inder D Kumar, et al. (+4)
98 [GO] 2021―Aug―09 Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis Evdoxia Kyriazopoulou, Thomas Huet, Giulio Cavalli, Andrea Gori, Miltiades Kyprianou, Peter Pickkers, et al. (+135)
99 [GO] 2021―Aug―09 A role for interleukin-1 receptor antagonism in severe COVID-19? Rachel S Tattersall, Dennis McGonagle, Jessica J Manson
100 [GO] 2021―Aug―06 Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies Laura Boekel, Maurice Steenhuis, Femke Hooijberg, Yaëlle R Besten, Zoé L E van Kempen, Laura Y Kummer, et al. (+18)
101 [GO] 2021―Jul―22 Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases Jonathan S Hausmann, Kevin Kennedy, Julia F Simard, Jean W Liew, Jeffrey A Sparks, Tarin T Moni, et al. (+146)
102 [GO] 2021―Jul―22 Adult-onset Still's disease following COVID-19 vaccination Flavia Leone, Pier Giacomo Cerasuolo, Silvia Laura Bosello, Lucrezia Verardi, Enrica Fiori, Fabrizio Cocciolillo, et al. (+3)
103 [GO] 2021―Jul―22 Adult-onset Still's disease after mRNA COVID-19 vaccine Daniel Magliulo, Soumya Narayan, Frances Ue, Afroditi Boulougoura, Fadi Badlissi
104 [GO] 2021―Jul―22 Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases Alessandro Antonelli, Poupak Fallahi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, et al. (+3)
105 [GO] 2021―Jul―21 Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study Renaud Felten, Lou Kawka, Maxime Dubois, Manuel F Ugarte-Gil, Yurilis Fuentes-Silva, Matteo Piga, Laurent Arnaud
106 [GO] 2021―Jul―08 Impact of methotrexate on first-dose COVID-19 mRNA vaccination Caoilfhionn M Connolly, Julie J Paik
107 [GO] 2021―Jul―08 The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study Satveer K Mahil, Katie Bechman, Antony Raharja, Clara Domingo-Vila, David Baudry, Matthew A Brown, et al. (+15)
108 [GO] 2021―Jul―06 Reactivation of IgA vasculitis after COVID-19 vaccination Michel Obeid, Craig Fenwick, Giuseppe Pantaleo
109 [GO] 2021―Jun―18 First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea Karen Schreiber, Oliver Hendricks
110 [GO] 2021―Jun―18 Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study Youn Ho Shin, Jae Il Shin, Sung Yong Moon, Hyun Young Jin, So Young Kim, Jee Myung Yang, et al. (+15)
111 [GO] 2021―Jun―18 Adverse events after first COVID-19 vaccination in patients with autoimmune diseases Laura Boekel, Laura Y Kummer, Koos P J van Dam, Femke Hooijberg, Zoé van Kempen, Erik H Vogelzang, et al. (+11)
112 [GO] 2021―Jun―08 Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study Jackeline J Rodriguez-Smith, Emely L Verweyen, Gwendolyn M Clay, Ysabella M Esteban, Sarah R de Loizaga, Elizabeth Joy Baker, et al. (+6)
113 [GO] 2021―May―28 Defining COVID-19-associated hyperinflammatory syndrome in specific populations Brandon J Webb
114 [GO] 2021―May―28 Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study Tiffany Y-T Hsu, Kristin M D'Silva, Naomi J Patel, Jiaqi Wang, Alisa A Mueller, Xiaoqing Fu, et al. (+10)
115 [GO] 2021―May―27 Going viral: misinformation in the time of COVID-19 The Lancet Rheumatology
116 [GO] 2021―May―27 COVID-19 vaccination advice via SMS-based video to improve vaccination uncertainty in at-risk groups James Bateman, Natasha Cox, Lavanya Rajagopala, Mark Ford, Muhamad Jasim, Diarmuid Mulherin, et al. (+4)
117 [GO] 2021―May―27 Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2 Martin Aringer
118 [GO] 2021―May―27 Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort Amit Saxena, Allison Guttmann, Mala Masson, Mimi Y Kim, Rebecca H Haberman, Rochelle Castillo, et al. (+78)
119 [GO] 2021―May―07 Non-steroidal anti-inflammatory drug use in COVID-19 Kristian Kragholm, Christian Torp-Pedersen, Emil Fosbol
120 [GO] 2021―May―07 Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study Thomas M Drake, Cameron J Fairfield, Riinu Pius, Stephen R Knight, Lisa Norman, Michelle Girvan, et al. (+356)
121 [GO] 2021―Apr―28 COVID-19 in patients with rheumatic disease: finally, a denominator Daniel J Wallace
122 [GO] 2021―Apr―28 SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study David Saadoun, Matheus Vieira, Mathieu Vautier, Xenofon Baraliakos, Ioana Andreica, José A P da Silva, et al. (+16)
123 [GO] 2021―Apr―19 A complex intervention to improve anxiety in people with systemic sclerosis during COVID-19 Jill M Newby
124 [GO] 2021―Apr―19 Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial Brett D Thombs, Linda Kwakkenbos, Brooke Levis, Angelica Bourgeault, Richard S Henry, Alexander W Levis, et al. (+23)
125 [GO] 2021―Apr―06 Incident systemic rheumatic disease following COVID-19 Tiffany Y-T Hsu, Kristin M D'Silva, Naomi J Patel, Xiaoqing Fu, Zachary S Wallace, Jeffrey A Sparks
126 [GO] 2021―Mar―31 The role of antirheumatics in patients with COVID-19 Christoffer B Nissen, Savino Sciascia, Danieli de Andrade, Tatsuya Atsumi, Ian N Bruce, Randy Q Cron, et al. (+6)
127 [GO] 2021―Mar―31 Flare of rheumatoid arthritis after COVID-19 vaccination Katherine A Terracina, Filemon K Tan
128 [GO] 2021―Mar―27 First manifestation of adult-onset Still's disease after COVID-19 Anna D Bamidis, Philipp Koehler, Veronica di Cristanziano, Kurt Rasche, Baris Demirel, Petra Bacher, et al. (+6)
129 [GO] 2021―Mar―25 COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study Jérôme Avouac, Elodie Drumez, Eric Hachulla, Raphaèle Seror, Sophie Georgin-Lavialle, Soumaya El Mahou, et al. (+17)
130 [GO] 2021―Mar―25 Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic Maxime Dougados
131 [GO] 2021―Mar―19 Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial Paul C Cremer, Antonio Abbate, Kristin Hudock, Carla McWilliams, Jinesh Mehta, Steven Y Chang, et al. (+47)
132 [GO] 2021―Mar―19 COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics - Author's reply Dennis McGonagle, Charlie Bridgewood, Athimalaipet V Ramanan, James F M Meaney, Abdulla Watad
133 [GO] 2021―Mar―19 COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics Graham Lloyd-Jones, Matthijs Oudkerk
134 [GO] 2021―Mar―19 Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe? Puja Mehta, Rachel C Chambers, Lorenzo Dagna
135 [GO] 2021―Mar―19 Arthritis after SARS-CoV-2 infection Chokan Baimukhamedov, Tatiana Barskova, Marco Matucci-Cerinic
136 [GO] 2021―Mar―11 Patients with gout: an under-recognised group at high risk of COVID-19 Nicola Dalbeth, Philip C Robinson
137 [GO] 2021―Mar―09 Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation Juan Salvatierra, Ismael Francisco Aomar-Millán, José Hernández-Quero
138 [GO] 2021―Mar―09 Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply Giulio Cavalli, Alessandro Larcher, Alessandro Tomelleri, Lorenzo Dagna
139 [GO] 2021―Feb―23 Perspective of patients with autoimmune diseases on COVID-19 vaccination Laura Boekel, Femke Hooijberg, Zoé L E van Kempen, Erik H Vogelzang, Sander W Tas, Joep Killestein, et al. (+8)
140 [GO] 2021―Feb―23 Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases Renaud Felten, Maxime Dubois, Manuel F Ugarte-Gil, Aurore Chaudier, Lou Kawka, Hugo Bergier, et al. (+10)
141 [GO] 2021―Feb―06 Type I interferon, anti-interferon antibodies, and COVID-19 Leonard H Calabrese, Kevin Winthrop, Vibeke Strand, Jinoos Yazdany, Jolan E Walter
142 [GO] 2021―Feb―06 COVID-19 cytokine storm: targeting the appropriate cytokine Randy Q Cron
143 [GO] 2021―Feb―06 Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study Giulio Cavalli, Alessandro Larcher, Alessandro Tomelleri, Corrado Campochiaro, Emanuel Della-Torre, Giacomo De Luca, et al. (+14)
144 [GO] 2021―Jan―28 Too long to wait: the impact of COVID-19 on elective surgery The Lancet Rheumatology
145 [GO] 2021―Jan―28 Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this? Milena A Gianfrancesco, Philip C Robinson
146 [GO] 2021―Jan―27 Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? Luis Ayerbe, Carlos Risco-Risco, Iván Núñez-Gil, Maria Perez-Piñar, Salma Ayis
147 [GO] 2021―Jan―27 Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? - Authors' reply Christopher T Rentsch, Nicholas J DeVito, Brian MacKenna, Caroline E Morton, Krishnan Bhaskaran, Jeremy P Brown, et al. (+27)
148 [GO] 2021―Jan―19 Divergent effects of acute versus chronic glucocorticoids in COVID-19 Philip C Robinson, Eric Morand
149 [GO] 2021―Jan―14 COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Lorenzo Dagna, Valeria Riccieri, Elisabetta Zanatta, et al. (+117)
150 [GO] 2021―Jan―10 COVID-19 vasculitis and novel vasculitis mimics Dennis McGonagle, Charlie Bridgewood, Athimalaipet V Ramanan, James F M Meaney, Abdulla Watad
151 [GO] 2021―Jan―10 Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis Puja Mehta, Dorian O Haskard, Michael A Laffan, Rachel C Chambers, Beverley J Hunt
152 [GO] 2020―Dec―24 Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study April Jorge, Kristin M D'Silva, Andrew Cohen, Zachary S Wallace, Natalie McCormick, Yuqing Zhang, Hyon K Choi
153 [GO] 2020―Dec―24 SARS-CoV-2 serological cross-reactivity with autoantibodies Kay Weng Choy
154 [GO] 2020―Dec―24 SARS-CoV-2 serological cross-reactivity with autoantibodies - Authors' reply Jialin Teng, Jin Dai
155 [GO] 2020―Dec―17 Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 Christoph Garbers, Stefan Rose-John
156 [GO] 2020―Dec―17 Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 - Authors' reply Jonas Bovijn, Cecilia M Lindgren, Michael V Holmes
157 [GO] 2020―Dec―16 Efficacy matters: broadening complement inhibition in COVID-19 Dimitrios C Mastellos, Panagiotis Skendros, Rodrigo T Calado, Antonio M Risitano, John D Lambris
158 [GO] 2020―Dec―16 Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply Alexander P J Vlaar, Sanne de Bruin, Matthijs C Brouwer, Diederik van de Beek
159 [GO] 2020―Dec―09 Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective Sarah L Mackie, Elisabeth Brouwer, Richard Conway, Kornelis S M van der Geest, Puja Mehta, Susan P Mollan, et al. (+4)
160 [GO] 2020―Dec―03 Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice Puja Mehta, Karim Meeran, Elizabeth Macphie, Afroze Abbas, Jonathan Rippin, Rachel C Jeffery, et al. (+5)
161 [GO] 2020―Dec―01 COVID-19 in axial spondyloarthritis care provision: helping to straighten the long and winding road Helena Marzo-Ortega, Simon Whalley, Jill Hamilton, Dale Webb
162 [GO] 2020―Nov―24 First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection Lea Perrot, Marie Hemon, Jean-Marc Busnel, Olivier Muis-Pistor, Christophe Picard, Christine Zandotti, et al. (+4)
163 [GO] 2020―Nov―10 Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma Puja Mehta, Emilie Sanchez, Elena Moraitis, Nicky Longley, Dennis W Lendrem, Ian P Giles, et al. (+3)
164 [GO] 2020―Nov―06 Hydroxychloroquine in the prevention of COVID-19 mortality April Jorge
165 [GO] 2020―Nov―06 Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform Christopher T Rentsch, Nicholas J DeVito, Brian MacKenna, Caroline E Morton, Krishnan Bhaskaran, Jeremy P Brown, et al. (+27)
166 [GO] 2020―Oct―30 Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians Karen Schreiber, Savino Sciascia, Ian N Bruce, Ian Giles, Maria J Cuadrado, Hannah Cohen, et al. (+13)
167 [GO] 2020―Oct―09 Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? Gaetano Zizzo, Philip L Cohen
168 [GO] 2020―Oct―05 Viral arthritis and COVID-19 Simone Parisi, Richard Borrelli, Sabina Bianchi, Enrico Fusaro
169 [GO] 2020―Sep―30 COVID-19 and African rheumatology: progress in adversity Richard O Akintayo, Asgar Kalla, Adewale Adebajo
170 [GO] 2020―Sep―29 Defining the scourge of COVID-19 hyperinflammatory syndrome Randy Q Cron, Grant S Schulert, Rachel S Tattersall
171 [GO] 2020―Sep―29 Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study Brandon J Webb, Ithan D Peltan, Paul Jensen, Daanish Hoda, Bradley Hunter, Aaron Silver, et al. (+9)
172 [GO] 2020―Sep―28 The opening salvo of anti-complement therapy against COVID-19 Courtney M Campbell
173 [GO] 2020―Sep―28 Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial Alexander P J Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd A M E G Timmermans, Ingeborg E van Zeggeren, Rutger Koning, et al. (+20)
174 [GO] 2020―Sep―25 Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19 Jonas Bovijn, Cecilia M Lindgren, Michael V Holmes
175 [GO] 2020―Sep―24 High-stakes heterogeneity in COVID-19 The Lancet Rheumatology
176 [GO] 2020―Sep―21 The contribution of the observational research design to COVID-19 research Alfred H J Kim, Seth A Eisen
177 [GO] 2020―Sep―21 Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study Chris A Gentry, Mary Beth Humphrey, Sharanjeet K Thind, Sage C Hendrickson, George Kurdgelashvili, Riley J Williams
178 [GO] 2020―Sep―17 Tocilizumab in COVID-19: finding the optimal route and dose Siddharth Jain, Sanjay Jain, Shefali Khanna Sharma
179 [GO] 2020―Sep―17 Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply Giovanni Guaraldi, Jovana Milic, Alessandro Cozzi-Lepri, Federico Pea, Cristina Mussini
180 [GO] 2020―Sep―09 COVACTA trial raises questions about tocilizumab's benefit in COVID-19 Bryant Furlow
181 [GO] 2020―Sep―06 Mavrilimumab for severe COVID-19 Adil Rashid Khan, Manish Soneja, Praveen Kumar Tirlangi, Naveet Wig
182 [GO] 2020―Sep―06 Mavrilimumab for severe COVID-19 Mohamad Amin Pourhoseingholi, Sajad Shojaee, Sara Ashtari
183 [GO] 2020―Sep―06 Mavrilimumab for severe COVID-19 - Authors' reply Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, Emanuel Della-Torre, Lorenzo Dagna
184 [GO] 2020―Sep―06 Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment Philip C Robinson, Duncan Richards, Helen L Tanner, Marc Feldmann
185 [GO] 2020―Aug―27 Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population Femke Hooijberg, Laura Boekel, Erik H Vogelzang, Maureen Leeuw, Maarten Boers, Ronald van Vollenhoven, et al. (+3)
186 [GO] 2020―Aug―21 Delving beneath the surface of hyperinflammation in COVID-19 Kiran Reddy, Angela J Rogers, Daniel F McAuley
187 [GO] 2020―Aug―21 COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study Jessica J Manson, Colin Crooks, Meena Naja, Amanda Ledlie, Bethan Goulden, Trevor Liddle, et al. (+30)
188 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia Jean-Jacques Mourad, Philippe Azria
189 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia Salvatore Piano, Roberto Vettor, Paolo Angeli, G Arcidiacono, D Benfaremo, S Bettini, et al. (+25)
190 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia Brian J Lipworth, Rory Chan, Chris RuiWen Kuo
191 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia - Authors' reply Giovanni Guaraldi, Marianna Meschiari, Jovana Milic, Alessandro Cozzi-Lepri, Cristina Mussini
192 [GO] 2020―Aug―14 The conundrum of interleukin-6 blockade in COVID-19 Corrado Campochiaro, Lorenzo Dagna
193 [GO] 2020―Aug―14 Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study Noa Biran, Andrew Ip, Jaeil Ahn, Ronaldo C Go, Shuqi Wang, Shivam Mathura, et al. (+23)
194 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 Adil Rashid Khan, Manish Soneja, Netto George, Naveet Wig
195 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 Laine Marc, Bonello Laurent
196 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 Naim Akhtar Khan
197 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 - Authors' reply Gilles Hayem, Thomas Huet, Stéphane Jouveshomme, Hélène Beaussier, Gilles Chatellier, Jean-Jacques Mourad
198 [GO] 2020―Jul―31 B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Puja Mehta, Joanna C Porter, Rachel C Chambers, David A Isenberg, Venkat Reddy
199 [GO] 2020―Jul―29 Opioid use in rheumatic diseases: preventing another pandemic The Lancet Rheumatology
200 [GO] 2020―Jul―24 Effect of anakinra in COVID-19 Emma J Kooistra, Nicole J B Waalders, Matthijs Kox, Peter Pickkers
201 [GO] 2020―Jul―24 Effect of anakinra in COVID-19 - Authors' reply Giulio Cavalli, Lorenzo Dagna
202 [GO] 2020―Jul―13 Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection Rosaria Talarico, Chiara Stagnaro, Francesco Ferro, Linda Carli, Marta Mosca
203 [GO] 2020―Jul―10 Severe refractory Kawasaki disease in seven infants in the COVID-19 era Stefania Vergnano, Nele Alders, Catherine Armstrong, Andrew R Bamber, Srini Bandi, Jennifer A Evans, et al. (+7)
204 [GO] 2020―Jul―10 Iloprost for COVID-19-related vasculopathy Carine J Moezinia, Antonio Ji-Xu, Arianna Azari, Serena Horlick, Christopher Denton, Richard Stratton
205 [GO] 2020―Jul―03 COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study Jixin Zhong, Guifen Shen, Huiqin Yang, Anbin Huang, Xiaoqi Chen, Li Dong, et al. (+14)
206 [GO] 2020―Jun―29 COVID-19 in children and young people Susanna Felsenstein, Christian M Hedrich
207 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia Hisyovi Cárdenas Suri
208 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia Giovanni Brondani, Luca Apollonio, Elisa Gremese, Gianfranco Ferraccioli
209 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia Brandon P Reines, Barry W Ninham
210 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia - Authors' reply Dennis McGonagle, James S O'Donnell, Kassem Sharif, Paul Emery, Charles Bridgewood
211 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 Omar Maoujoud, Mohammed Asserraji, Samir Ahid, Marouane Belarbi, Nadir Zemraoui
212 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 Xavier Valette, Damien du Cheyron
213 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 Nicolas Martin-Silva, Hubert de Boysson, Achille Aouba
214 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 - Authors' reply Giulio Cavalli, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna
215 [GO] 2020―Jun―24 Tocilizumab in patients with severe COVID-19: a retrospective cohort study Giovanni Guaraldi, Marianna Meschiari, Alessandro Cozzi-Lepri, Jovana Milic, Roberto Tonelli, Marianna Menozzi, et al. (+28)
216 [GO] 2020―Jun―24 Can tocilizumab calm the cytokine storm of COVID-19? Grant S Schulert
217 [GO] 2020―Jun―18 COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study Micaela Fredi, Ilaria Cavazzana, Liala Moschetti, Laura Andreoli, Franco Franceschini, Paolo Airò, et al. (+17)
218 [GO] 2020―Jun―16 GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, Emanuel Della-Torre, Piera Angelillo, Alessandro Tomelleri, et al. (+16)
219 [GO] 2020―Jun―16 GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? Ennio Giulio Favalli, Roberto Caporali
220 [GO] 2020―Jun―08 Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic? Su-Ann Yeoh, Michael R Ehrenstein
221 [GO] 2020―Jun―04 Canakinumab in a subgroup of patients with COVID-19 Claudio Ucciferri, Antonio Auricchio, Marta Di Nicola, Nicola Potere, Antonio Abbate, Francesco Cipollone, et al. (+2)
222 [GO] 2020―Jun―01 Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic Helena Marzo-Ortega, Ai Lyn Tan, Lesley-Anne Bissell, Ann W Morgan, Claire Vandevelde, Edward M Vital, Shouvik Dass
223 [GO] 2020―May―29 Anakinra for severe forms of COVID-19: a cohort study Thomas Huet, Hélène Beaussier, Olivier Voisin, Stéphane Jouveshomme, Gaëlle Dauriat, Isabelle Lazareth, et al. (+11)
224 [GO] 2020―May―29 Coronavirus is the trigger, but the immune response is deadly Randy Q Cron
225 [GO] 2020―May―27 Hydroxychloroquine: balancing the needs of LMICs during the COVID-19 pandemic Soumya Banerjee
226 [GO] 2020―May―27 COVID-19: a time to reflect The Lancet Rheumatology
227 [GO] 2020―May―26 COVID-19 and systemic lupus erythematosus: a case series Yevgeniya Gartshteyn, Anca D Askanase, Nancyanne M Schmidt, Elana J Bernstein, Leila Khalili, Rachel Drolet, et al. (+3)
228 [GO] 2020―May―21 Anakinra in COVID-19: important considerations for clinical trials Andrew King, Andy Vail, Claire O'Leary, Cathal Hannan, David Brough, Hiren Patel, et al. (+6)
229 [GO] 2020―May―21 The immunology of COVID-19: is immune modulation an option for treatment? Jixin Zhong, Jungen Tang, Cong Ye, Lingli Dong
230 [GO] 2020―May―18 Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases Jialin Teng, Jin Dai, Yutong Su, Zhuochao Zhou, Huihui Chi, Liyan Wan, et al. (+12)
231 [GO] 2020―May―16 Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms Clare E Pain, Susanna Felsenstein, Gavin Cleary, Sarah Mayell, Karsten Conrad, Srikrishna Harave, et al. (+4)
232 [GO] 2020―May―07 Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Giulio Cavalli, Giacomo De Luca, Corrado Campochiaro, Emanuel Della-Torre, Marco Ripa, Diana Canetti, et al. (+17)
233 [GO] 2020―May―07 Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Dennis McGonagle, James S O'Donnell, Kassem Sharif, Paul Emery, Charles Bridgewood
234 [GO] 2020―May―07 Should COVID-19 take advice from rheumatologists? Kate F Kernan, Scott W Canna
235 [GO] 2020―May―06 Rapid distribution of information by SMS-embedded video link to patients during a pandemic James Bateman, Diarmuid Mulherin, George Hirsch, Srinivasan Venkatachalam, Tom Sheeran
236 [GO] 2020―May―05 Initial data from the COVID-19 Global Rheumatology Alliance provider registries Anthony Vanjak
237 [GO] 2020―May―05 Initial data from the COVID-19 Global Rheumatology Alliance provider registries - Authors' reply Milena A Gianfrancesco
238 [GO] 2020―Apr―16 Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries Milena A Gianfrancesco, Kimme L Hyrich, Laure Gossec, Anja Strangfeld, Loreto Carmona, Elsa F Mateus, et al. (+11)
239 [GO] 2020―Apr―16 Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community The Lancet Rheumatology
240 [GO] 2020―Apr―06 Global rheumatology in the time of COVID-19 Laura B Lewandowski, Evelyn Hsieh
241 [GO] 2020―Apr―06 Preventing COVID-19-induced pneumonia with anticytokine therapy Giovanni Monteleone, Pier Carlo Sarzi-Puttini, Sandro Ardizzone
242 [GO] 2020―Apr―04 Rheumatologists rapidly adjust patient care during COVID-19 pandemic Tony Kirby
243 [GO] 2020―Apr―02 Caution and clarity required in the use of chloroquine for COVID-19 Yin Kwan Wong, Jing Yang, Yingke He
244 [GO] 2020―Apr―01 Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology Brian Owens
 [1] 

244 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.009 sec